Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Bhavanadhar Penta

Interventional Cardiology New York, NY Medical Doctor

NPI 1669171781 CMS profile 11448500

1190 5Th Ave, New York, NY 10029

Open in the dashboard

General payments

$17,895

393 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bhavanadhar Penta of New York, NY is reported in the CMS Open Payments database as having received $17,895 across 393 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,844 112
2024 General $10,941 213
2023 General $2,110 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bhavanadhar Penta
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Bhavanadhar Penta were reported at $4,844. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Bhavanadhar Penta Interventional Cardiology median Middle half National median
2019 $0 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $0 $677 $233–$1,827 $132
2022 $0 $978 $333–$2,724 $149
2023 $2,110 $1,136 $382–$2,986 $160
2024 $10,941 $1,181 $395–$3,326 $164
2025 $4,844 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Boston Scientific Corporation $3,156 33 payments
  2. Edwards Lifesciences Corporation $2,451 28 payments
  3. Shockwave Medical, Inc $2,235 51 payments
  4. Abbott Laboratories $1,694 25 payments
  5. Abiomed $1,407 44 payments
  6. Cardiva Medical, Inc. $1,333 45 payments
  7. Medtronic, Inc. $1,006 11 payments
  8. Terumo Medical Corporation $726 22 payments
  9. Biotronik Inc. $665 16 payments
  10. Chiesi USA, Inc. $594 25 payments
  11. Other $2,629 93 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $12,625 371 payments
  2. Travel and Lodging $4,206 20 payments
  3. Grant $1,063 1 payment
  4. Education $1 1 payment
Products named General payments · program years 2023–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $2,004 41 payments
  2. PASCAL $1,676 20 payments
  3. AMPLATZER $1,079 11 payments
  4. Impella $982 32 payments
  5. Cardiva VASCADE 5F VCS $913 30 payments
  6. COREVALVE EVOLUT R $630 9 payments
  7. KENGREAL $594 25 payments
  8. Orsiro Mission $579 14 payments
  9. NAVITOR $338 9 payments
  10. LUTONIX Drug Coated Balloon $334 13 payments
  11. Other $4,951 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

393 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record